# Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

> **NCT03493646** · PHASE2 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 40 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** CC-486

## Key facts

- **NCT ID:** NCT03493646
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2020-09-15
- **Final completion:** 2021-09-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493646, "Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03493646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*